Vioxx Withdrawal and Drug Litigation

Written by Richard Martin

On Sept. 30, 2004 Merck announced a worldwide withdrawal of Vioxx® (rofecoxib). Vioxx had previously been prescribed inrepparttar treatment of arthritis and pain. Worldwide sales of Vioxx in 2003 were an estimated $2.5Billion andrepparttar 119226 drug was marketed in more than 80 countries aroundrepparttar 119227 world. This is one of several recent pharmaceutical products to have been put inrepparttar 119228 spotlight by bothrepparttar 119229 national media and plaintiff lawyers. Since sometime inrepparttar 119230 mid to late 90s a substantial number of pharmaceutical medications and medical devices have been removed fromrepparttar 119231 market due to possible adverse health implications. The FDA acts as a regulatory body in approving health related products before they are marketed to consumers. The FDA moved to ban Ephedra inrepparttar 119232 US in 2004. However,repparttar 119233 recent headlines about voluntary drug withdrawals have produced questions as torepparttar 119234 FDA's recent performance. Many people believe thatrepparttar 119235 FDA did not testrepparttar 119236 drugs rigorously enough to determine allrepparttar 119237 possible health problems that they might cause. People believe thatrepparttar 119238 rise in litigation over these medications was due torepparttar 119239 fact thatrepparttar 119240 FDA now allows pharmaceutical companies to “fast track” their products and get them throughrepparttar 119241 process in a year. In fact, Vioxx was only released in 1999.

The Right Focus on Tort Reform

Written by Richard Martin

The recent headlines about Merck's Vioxx withdrawal andrepparttar FDA's move to ban ephedra have brought a lot of media attention torepparttar 119225 growing area of drug litigation. On April 12, 2004repparttar 119226 FDA published a rule banning health supplements that contain ephedra alkaloids. The FDA concluded thatrepparttar 119227 limited short term weight loss effects were outweighed by possible heart problems and stroke risks. The market gap caused byrepparttar 119228 banning of ephedra has been filled by many new companies that are marketing products similar to ephedra. However, these “ephedra alternatives” may not be any safer thanrepparttar 119229 banned ephedra that they replace. The FDA's ephedra ban, and Merck's Vioxx withdrawal have been hot news topics. These drug recalls and ephedra banning have brought lawsuits from many different angles. Obviously, some people think that some ofrepparttar 119230 lawsuits will be frivolous. In fact, there has been a lot of news duringrepparttar 119231 last decade about “frivolous lawsuits” brought by injured consumers against large companies for defective products. However, according to one report from Public Citizen ( ), businesses file many more timesrepparttar 119232 amount of lawsuits than consumers do and are more likely to be sanctioned by a court for bringing a frivolous claim.

Cont'd on page 2 ==> © 2005
Terms of Use